[144] Emergent Biosolutions, Inc. SEC Filing

Rhea-AI Filing Summary

Emergent Biosolutions (EBS) filed a Form 144 reporting a proposed sale of 7,844 shares of common stock that were acquired as restricted stock from the issuer on 05/08/2025. The filing lists an aggregate market value of $67,830.99 for the shares and shows 53,351,099 shares outstanding for the issuer. The seller reports an approximate date of sale of 08/12/2025 and the transaction is to occur on the NYSE through Morgan Stanley Smith Barney LLC Executive Financial Services.

The form indicates no securities sold in the past three months by the person for whose account these securities are to be sold and includes the standard representation that the signer does not possess undisclosed material adverse information about the issuer.

Insights

Securities Analyst

TL;DR: Routine Form 144 disclosing a proposed sale of restricted shares with no recent prior sales; appears immaterial based on filing details.

The filing reports a proposed disposition of 7,844 common shares acquired as restricted stock from the issuer on 05/08/2025, with an aggregate market value of $67,830.99. The seller reports no sales in the prior three months, and the transaction is directed to occur on the NYSE via Morgan Stanley Smith Barney LLC. From a market-impact perspective, the filing reads like a routine insider liquidity notice rather than a sign of broader corporate issues, given the specific acquisition type and absence of recent disposals.

Corporate Governance Expert

TL;DR: Insider received restricted stock and has notified intent to sell; disclosure aligns with Rule 144 requirements and includes customary certifications.

The form documents that the securities were received as restricted stock directly from the issuer and notes the seller's representation that they do not possess undisclosed material adverse information. The notice also states no securities sold in the past three months, which may be relevant to aggregation rules under Rule 144. Procedurally, the filing includes the required broker, share count, aggregate value, and planned sale date, meeting standard disclosure elements for such transactions.

Form 144 Filer Information	UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 Form 144 NOTICE OF PROPOSED SALE OF SECURITIES PURSUANT TO RULE 144 UNDER THE SECURITIES ACT OF 1933
FORM 144

144: Filer Information

Filer CIK
Filer CCC
Is this a LIVE or TEST Filing?	LIVE TEST
Submission Contact Information
Name
Phone
E-Mail Address

144: Issuer Information

Name of Issuer

SEC File Number

Address of Issuer

Phone

Name of Person for Whose Account the Securities are To Be Sold

See the definition of "person" in paragraph (a) of Rule 144. Information is to be given not only as to the person for whose account the securities are to be sold but also as to all other persons included in that definition. In addition, information shall be given as to sales by all persons whose sales are required by paragraph (e) of Rule 144 to be aggregated with sales for the account of the person filing this notice.

Relationship to Issuer

144: Securities Information

Title of the Class of Securities To Be Sold	Name and Address of the Broker	Number of Shares or Other Units To Be Sold	Aggregate Market Value	Number of Shares or Other Units Outstanding	Approximate Date of Sale	Name the Securities Exchange
Common	Morgan Stanley Smith Barney LLC Executive Financial Services 1 New York Plaza 8th Floor New York NY 10004	7844	67830.99	53351099	08/12/2025	NYSE

Furnish the following information with respect to the acquisition of the securities to be sold and with respect to the payment of all or any part of the purchase price or other consideration therefor:

144: Securities To Be Sold

Title of the Class	Date you Acquired	Nature of Acquisition Transaction	Name of Person from Whom Acquired	Is this a Gift?	Date Donor Acquired	Amount of Securities Acquired	Date of Payment	Nature of Payment *
Common	05/08/2025	Restricted Stock	Issuer			7844	05/08/2025	Not Applicable

* If the securities were purchased and full payment therefor was not made in cash at the time of purchase, explain in the table or in a note thereto the nature of the consideration given. If the consideration consisted of any note or other obligation, or if payment was made in installments describe the arrangement and state when the note or other obligation was discharged in full or the last installment paid.

Furnish the following information as to all securities of the issuer sold during the past 3 months by the person for whose account the securities are to be sold.

144: Securities Sold During The Past 3 Months

Nothing to Report

144: Remarks and Signature

Remarks

Date of Notice

ATTENTION:

The person for whose account the securities to which this notice relates are to be sold hereby represents by signing this notice that he does not know any material adverse information in regard to the current and prospective operations of the Issuer of the securities to be sold which has not been publicly disclosed. If such person has adopted a written trading plan or given trading instructions to satisfy Rule 10b5-1 under the Exchange Act, by signing the form and indicating the date that the plan was adopted or the instruction given, that person makes such representation as of the plan adoption or instruction date.

Signature

ATTENTION: Intentional misstatements or omission of facts constitute Federal Criminal Violations (See 18 U.S.C. 1001)

FAQ

What does the EBS Form 144 report?

The form reports a proposed sale of 7,844 common shares acquired as restricted stock from the issuer on 05/08/2025, with aggregate value $67,830.99.

When is the proposed sale scheduled and where will it occur?

The filing lists an approximate sale date of 08/12/2025 and indicates the securities are to be sold on the NYSE through Morgan Stanley Smith Barney LLC Executive Financial Services.

Were any EBS shares sold by this person in the past three months?

No. The Form 144 states Nothing to Report under securities sold during the past three months.

How were the shares being sold acquired?

The shares were acquired as restricted stock from the issuer on 05/08/2025, and payment/date of acquisition is recorded as 05/08/2025.

Does the filer assert possession of undisclosed material information?

By signing, the person represents that they do not know any material adverse information about the issuer that has not been publicly disclosed.